RMB, Big players would have been able to see through the numbers a year ago. It was obvious that the generic companies weren't capable of stealing the whole Vascepa market. Whatever the reason. There wasn't a direct relationship between increasing generic prescriptions and decreasing Vascepa prescriptions. You and I actually had conversations about this. Share price is driven by the opinion/feelings of average investors. Institutional traders tend to wait until there is an obvious tipping point. Something that an average person can see and understand. That hasn't happened yet. Things like the R-IT read out and patent loss are the things that average investors can grasp. Most institutional investors don't like dead money. They don't care about missing a few bucks on an upswing. Sleven,
News 
Market Data 
Discover 
